Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease
- 18 October 2010
- journal article
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 9 (1), 30-35
- https://doi.org/10.1016/j.cgh.2010.09.026
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Treatment of Severe Ulcerative Colitis: Differences in Elderly Patients?Digestive Diseases, 2009
- TNF‐α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical PracticeAnnals of the New York Academy of Sciences, 2009
- Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infectionsAlimentary Pharmacology & Therapeutics, 2009
- Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritisArthritis & Rheumatism, 2007
- Tolerance and effectiveness of anti–tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: A population‐based cohort studyArthritis Care & Research, 2007
- Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT RegistryClinical Gastroenterology and Hepatology, 2006
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I TrialGastroenterology, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Treatment of Inflammatory Bowel Disease in the ElderlyDrugs & Aging, 2002
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999